Transcatheter Mitral Valve Repair (TMVR) Improves Survival Rate in Patients with Heart Failure, Study Shows

A study has revealed that the Transcatheter mitral valve repair (TMVR) is safe, provides a durable decline in mitral regurgitation (MR), decreases rate of heart failure (HF) hospitalization, and enhances survival, quality of life, and functional capacity in patients with HF and moderate-to-severe or severe mitral regurgitation (MR) who remained symptomatic despite guideline-directed medical therapy (GDMT).


Photo: Heart Failure | InStyleHealth


The researchers said, “Surviving patients who crossed over to device treatment had a prognosis comparable to those originally assigned to transcatheter therapy.”


The study covered a total of 614 HF patients with moderate-to-severe or severe secondary mitral regurgitation (MR), who continued to be symptomatic despite maximally tolerated GDMT, were randomized to TMVR plus GDMT or GDMT alone. Heart failure (HF) hospitalizations through 24-mont-follow-up was the fundamental endpoint. Patients under study were monitored for 36 months.


Heart failure hospitalizations annualized rate per patient-per-year was lower in the TMVR group comparative to the GMDT alone group (35.5% vs 68.8%). Mortality rate was also found to be lower in the device group in comparison to the control group (42.8% vs 55.5%). Furthermore, patients who underwent TMVR had endured 3-year improvements in MR severity, quality of life measures, and functional capacity.


HF hospitalization’s subsequent composite mortality rate also reduced in 58 patients assigned to GDMT alone who crossed over and were treated with TMVR as opposed to those who sustained on GDMT alone. For complete details of the study, click here.


Source: J Am Coll Cardiol 2021;77:1029-1040


If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post